controlled substances
Psychedelic therapy: A new approach to mental health
December 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LSD, MDMA, controlled substances, depression, mental health, pharma, psychotherapy
In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
